ABOS ACUMEN PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended September 30, 2026, ACUMEN PHARMACEUTICALS INC reported revenue of n/a, net income of −$25.4M and diluted EPS of −$0.35; for the fiscal year ended December 2025 revenue was n/a.
ABOS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$124M, net income −$121M (margin n/a), EPS −$2.00
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$114M, net income −$102M (margin n/a), EPS −$1.71
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$61.1M, net income −$52.4M (margin n/a), EPS −$1.08
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$45.2M, net income −$42.9M (margin n/a), EPS −$1.06
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$19.6M, net income −$101M (margin n/a), EPS −$5.02
ABOS quarterly revenue and earnings
- Quarter ended Sep 30, 2026: revenue n/a, net income −$25.4M, EPS −$0.35
- Quarter ended Jun 30, 2026: revenue n/a, net income −$32.7M, EPS −$0.45
- Quarter ended Mar 31, 2026: revenue n/a, net income −$20.7M, EPS −$0.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$25.1M, EPS −$0.40
- Quarter ended Sep 30, 2025: revenue n/a, net income −$26.5M, EPS −$0.44
- Quarter ended Jun 30, 2025: revenue n/a, net income −$41.0M, EPS −$0.68
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.8M, EPS −$0.48
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$37.2M, EPS −$0.62
- Quarter ended Sep 30, 2024: revenue n/a, net income −$29.8M, EPS −$0.50
- Quarter ended Jun 30, 2024: revenue n/a, net income −$20.5M, EPS −$0.34
- Quarter ended Mar 31, 2024: revenue n/a, net income −$14.9M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$16.5M, EPS −$0.28
- Quarter ended Sep 30, 2023: revenue n/a, net income −$13.0M, EPS −$0.24
- Quarter ended Jun 30, 2023: revenue n/a, net income −$11.6M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.3M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$12.9M, EPS −$0.32
- Quarter ended Sep 30, 2022: revenue n/a, net income −$10.7M, EPS −$0.26
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.2M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue n/a, net income −$9.13M, EPS −$0.23
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$8.35M, EPS $201.42
ABOS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$116M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$86.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$43.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$35.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$18.0M, share buybacks n/a
ABOS balance sheet
- Sep 30, 2026: cash $53.1M, total assets $85.6M, total liabilities $51.0M, shareholders' equity $34.6M
- Jun 30, 2026: cash $59.4M, total assets $116M, total liabilities $58.7M, shareholders' equity $57.3M
- Mar 31, 2026: cash $51.8M, total assets $134M, total liabilities $46.2M, shareholders' equity $87.5M
- Dec 31, 2025: cash $54.0M, total assets $123M, total liabilities $52.4M, shareholders' equity $70.4M
- Sep 30, 2025: cash $46.8M, total assets $142M, total liabilities $49.0M, shareholders' equity $93.2M
- Jun 30, 2025: cash $36.8M, total assets $172M, total liabilities $54.8M, shareholders' equity $117M
- Mar 31, 2025: cash $30.2M, total assets $204M, total liabilities $49.0M, shareholders' equity $156M
- Dec 31, 2024: cash $35.6M, total assets $239M, total liabilities $57.2M, shareholders' equity $182M
Is ABOS profitable?
No. ACUMEN PHARMACEUTICALS INC lost $104M over the last four quarters.
What is ABOS's EPS?
Diluted earnings per share over the last four quarters were −$1.53; −$0.35 in the latest quarter.